The long-term efficacy of azathioprine in steroid-dependent ulcerative colitis

Scandinavian Journal of Gastroenterology

Volumn 48, Issue 12, 2013, Pages 1386-1393

  Park, Soo Kyung ^a   Yang, Suk Kyun ^a   Ye, Byong Duk ^a   Kim, Kyung Jo ^a   Yang, Dong Hoon ^a   Jung, Kee Wook ^a   Park, Sang Hyoung ^a   Kim, Jong Wook ^b   Byeon, Jeong Sik ^a   Myung, Seung Jae ^a   Kim, Jin Ho ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

Azathioprine; Steroid dependency; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; INFLIXIMAB;

ADOLESCENT; ADULT; AGED; ARTICLE; COLON RESECTION; DRUG EFFICACY; DRUG FEVER; FEMALE; HAIR LOSS; HUMAN; HYPERTRANSAMINASEMIA; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MIDDLE AGED; NAUSEA AND VOMITING; PRIORITY JOURNAL; RELAPSE; REMISSION; TREATMENT OUTCOME; ULCERATIVE COLITIS; WEAKNESS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS; AZATHIOPRINE; COLITIS, ULCERATIVE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PREDNISOLONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84892151388     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2013.845908     Document Type: Article

References (39)

1. Stange EF, Travis SP, Vermeire S, Reinisch W, Geboes K, Barakauskiene A, et al. European evidence-based consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. J Crohns Colitis 2008;2:1-23
2. Katz J. The course of inflammatory bowel disease. Med Clin North Am 1994;78:1275-80
3. Edwards FC, Truelove SC. The course and prognosis of Ulcerative Colitis. Gut 1963;4:299-315
4. FaubionWA Jr, Loftus EV Jr, HarmsenWS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study. Gastroenterology 2001;121:255-60
5. Travis SP, Stange EF, Lemann M, Oresland T, Bemelman WA, Chowers Y, et al. European evidence-based consensus on the management of ulcerative colitis: Current management. J Crohns Colitis 2008;2:24-62
6. Leung Y, Panaccione R, Hemmelgarn B, Jones J. Exposing the weaknesses: A systematic review of azathioprine efficacy in ulcerative colitis. Dig Dis Sci 2008;53:1455-61
7. Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: A systematic review and metaanalysis. Am J Gastroenterol 2011;106:630-42
8. Timmer A, McDonald JW, Tsoulis DJ, Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;9:CD000478
9. Gisbert JP, Linares PM, McNicholl AG, Mate J, Gomollon F. Meta-analysis: The efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009;30:126-37
10. Satsangi J, Welsh KI, Bunce M, Julier C, Farrant JM, Bell JI, et al. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996;347:1212-17
11. Myung SJ, Yang SK, Jung HY, Chang HS, Park B, Hong WS, et al. HLA-DRB1. *1502 confers susceptibility to ulcerative colitis, but is negatively associated with its intractability: A Korean study. Int J Colorectal Dis 2002; 17:233-7
12. Park SH, Kim YM, Yang SK, Kim SH, Byeon JS, Myung SJ, et al. Clinical features and natural history of ulcerative colitis in Korea. Inflamm Bowel Dis 2007;13:278-83
13. Probert CSJ, Jayanthi V, Bhakta P, Wicks TCB, Mayberry JF. How necessary is colectomy? An epidemiological study of the surgical management of ulcerative colitis amongst different ethnic groups in Leicestershire. Eur J Gastroen Hepat 1993;5:17-20
14. Lee HJ, Yang SK, Kim KJ, Choe JW, Yoon SM, Ye BD, et al. The Safety and efficacy of azathioprine and 6-Mercaptopurine in the treatment of Korean patients with Crohn's Disease. Intest Res 2009;7:22-31
15. Takatsu N, Matsui T, Murakami Y, Ishihara H, Hisabe T, Nagahama T, et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J Gastroenterol Hepatol 2009;24:1258-64
16. Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol 2003;38:740-6
17. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989;170:2-6; discussion 16-9
18. Elion GB. The pharmacology of azathioprine. Ann NY Acad Sci 1977;21:401-7
19. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19:5-36
20. Steinhart AH, Baker JP, Brzezinski A, Prokipchuk EJ. Azathioprine therapy in chronic ulcerative colitis. J Clin Gastroenterol 1990;12:271-5
21. Lobo AJ, Foster PN, Burke DA, Johnston D, Axon AT. The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum 1990;33:374-7
22. Adler DJ, Korelitz BI. The therapeutic efficacy of 6- mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol 1990;85:717-22
23. George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6- mercaptopurine. Am J Gastroenterol 1996;91:1711-14
24. Ardizzone S, Molteni P, Imbesi V, Bollani S, Bianchi Porro G. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997;25:330-3
25. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: A 30 year review. Gut 2002;50:485-9
26. Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol 2001;13:1297-301
27. Kader HA, Mascarenhas MR, Piccoli DA, Stouffer NO, Baldassano RN. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Pediatr Gastroenterol Nutr 1999;28:54-8
28. Holtmann MH, Krummenauer F, Claas C, Kremeyer K, Lorenz D, Rainer O, et al. Long-term effectiveness of azathioprine in IBD beyond 4 years: A European multicenter study in 1176 patients. Dig Dis Sci 2006;51:1516-24
29. Lobel EZ, Korelitz BI, Xuereb MA, Panagopoulos G. A search for the optimal duration of treatment with 6- mercaptopurine for ulcerative colitis. Am J Gastroenterol 2004;99:462-5
30. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: Final report on controlled therapeutic trial. Br Med J 1974;4: 627-30
31. Rosenberg JL, Wall AJ, Levin B, Binder HJ, Kirsner JB. A controlled trial of azathioprine in the management of chronic ulcerative colitis. Gastroenterology 1975;69:96-9
32. Caprilli R, Carratu R, Babbini M. Double-blind comparison of the effectiveness of azathioprine and sulfasalazine in idiopathic proctocolitis. Preliminary report. Am J Dig Dis 1975; 20:115-20
33. Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 1982; 284:1291-2
34. Hawthorne AB, Logan RF, Hawkey CJ, Foster PN, Axon AT, Swarbrick ET, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305:20-2
35. Sood A, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: One-year, placebo-controlled, randomized trial. Indian J Gastroenterol 2000;19:14-16
36. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006;55:47-53
37. SoodA, Kaushal V,MidhaV, BhatiaKL,SoodN,Malhotra V. The beneficial effect of azathioprine on maintenance of remissioninsevereulcerativecolitis. JGastroenterol2002;37:270-4
38. Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: Azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996;91:423-33
39. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995;123:132-42